Australian Government - Department of Health

Medical Services Advisory Committee (MSAC)

1370 - Ocriplasmin for symptomatic vitreomacular adhesion (sVMA) including macular hole

The documents on this page may not be accessible, should you require assistance accessing the information please contact the MSAC Secretariat.
Application Number1370
Application NameOcriplasmin for symptomatic vitreomacular adhesion (sVMA) including macular hole
Description of Medical ServiceOptical coherence tomography (OCT) is part of standard
clinical practice for diagnosing a wide range of macular and retinal diseases. It is proposed that OCT be used as a procedure in patients with sVMA including those associated with full thickness macular hole (FTMH) for the purpose of identifying eligibility for treatment with ocriplasmin (on the Pharmaceutical Benefits Scheme); and for assessment of treatment outcome.
Description of Medical ConditionVitreomacular interface disorders describe a group of pathologies each with their own distinctive features that distort or blur vision and potentially impair central visual acuity, including vitreomacular adhesion/traction and macular holes.
Consultation Protocol7 February 2014 – 21 March 2014
PDF version Consultation Protocol (PDF 1825 KB)
Word version Consultation Protocol (Word 2427 KB)
Final Protocol PDF Version Final Protocol (PDF 939 KB)
Word Version Final Protocol (Word 1986 KB)
Reports-
MSAC OutcomesNovember 2014:
Public Summary Document (PDF 134 KB)
Public Summary Document (Word 111 KB)

March 2016:
Public Summary Document (PDF 63 KB)
Public Summary Document (Word 68 KB)

OCT broader implementation issues - MSAC's advice to the Minister:
OCT broader implementation issues (PDF 66 KB)
OCT broader implementation issues (Word 66 KB)

Meetings for this Application

Meeting Type:Date:
PASC12 to 13 December 2013
ESC 8 to 10 October 2014
MSAC 26 to 28 November 2014
30 to 31 March 2016

Page currency, Latest update: 08 June, 2016